Concepts (80)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Hematopoietic Stem Cell Transplantation | 16 | 2023 | 95 | 5.550 |
Why?
|
| Leukemia, Myeloid, Acute | 7 | 2022 | 46 | 2.760 |
Why?
|
| Graft vs Host Disease | 6 | 2023 | 33 | 2.580 |
Why?
|
| Bacterial Infections | 1 | 2023 | 41 | 0.860 |
Why?
|
| Hematologic Neoplasms | 2 | 2020 | 18 | 0.810 |
Why?
|
| Roseolovirus Infections | 1 | 2021 | 3 | 0.740 |
Why?
|
| Cord Blood Stem Cell Transplantation | 1 | 2021 | 5 | 0.740 |
Why?
|
| Transplantation Conditioning | 6 | 2022 | 31 | 0.730 |
Why?
|
| Core Binding Factor beta Subunit | 1 | 2020 | 2 | 0.720 |
Why?
|
| Oncogene Proteins, Fusion | 1 | 2020 | 10 | 0.720 |
Why?
|
| Granulocyte Precursor Cells | 1 | 2019 | 3 | 0.680 |
Why?
|
| Lymphoma, Large B-Cell, Diffuse | 1 | 2019 | 32 | 0.660 |
Why?
|
| Neoplasms | 1 | 2022 | 224 | 0.650 |
Why?
|
| Calcineurin Inhibitors | 3 | 2023 | 14 | 0.580 |
Why?
|
| Humans | 20 | 2023 | 25692 | 0.480 |
Why?
|
| Retrospective Studies | 6 | 2023 | 3220 | 0.390 |
Why?
|
| Precursor Cell Lymphoblastic Leukemia-Lymphoma | 2 | 2021 | 13 | 0.360 |
Why?
|
| Child, Preschool | 2 | 2023 | 640 | 0.340 |
Why?
|
| Leukemia, Myelogenous, Chronic, BCR-ABL Positive | 2 | 2020 | 9 | 0.340 |
Why?
|
| Risk Factors | 4 | 2020 | 2224 | 0.260 |
Why?
|
| Transplantation, Homologous | 5 | 2020 | 248 | 0.250 |
Why?
|
| Disease-Free Survival | 2 | 2022 | 152 | 0.240 |
Why?
|
| Recurrence | 3 | 2022 | 275 | 0.240 |
Why?
|
| Tacrolimus | 2 | 2021 | 14 | 0.230 |
Why?
|
| Cyclophosphamide | 1 | 2023 | 43 | 0.220 |
Why?
|
| Aged | 6 | 2023 | 8501 | 0.220 |
Why?
|
| Scedosporium | 1 | 2023 | 4 | 0.220 |
Why?
|
| Tissue Donors | 1 | 2023 | 61 | 0.210 |
Why?
|
| Vidarabine | 1 | 2022 | 8 | 0.200 |
Why?
|
| Middle Aged | 6 | 2022 | 8403 | 0.200 |
Why?
|
| Myelodysplastic Syndromes | 1 | 2022 | 29 | 0.200 |
Why?
|
| Immunosuppressive Agents | 2 | 2020 | 124 | 0.190 |
Why?
|
| Young Adult | 4 | 2020 | 1855 | 0.180 |
Why?
|
| Pain | 2 | 2021 | 372 | 0.180 |
Why?
|
| Leukemia, Myeloid, Chronic-Phase | 1 | 2020 | 1 | 0.180 |
Why?
|
| Leukocyte Count | 1 | 2020 | 62 | 0.180 |
Why?
|
| Prognosis | 2 | 2020 | 739 | 0.180 |
Why?
|
| Adult | 7 | 2022 | 7336 | 0.180 |
Why?
|
| Calcineurin | 1 | 2020 | 8 | 0.180 |
Why?
|
| Cell Count | 1 | 2020 | 66 | 0.170 |
Why?
|
| Pyrazines | 1 | 2019 | 9 | 0.170 |
Why?
|
| Gastrointestinal Tract | 1 | 2020 | 49 | 0.170 |
Why?
|
| Aniline Compounds | 1 | 2019 | 31 | 0.170 |
Why?
|
| Drug Resistance | 1 | 2019 | 37 | 0.160 |
Why?
|
| Steroids | 1 | 2019 | 23 | 0.160 |
Why?
|
| Typhlitis | 1 | 2019 | 2 | 0.160 |
Why?
|
| Mucositis | 1 | 2019 | 5 | 0.160 |
Why?
|
| Adolescent | 3 | 2020 | 2076 | 0.160 |
Why?
|
| Lung Diseases | 1 | 2019 | 42 | 0.160 |
Why?
|
| Coronavirus Infections | 1 | 2020 | 77 | 0.160 |
Why?
|
| Pneumonia, Viral | 1 | 2020 | 80 | 0.160 |
Why?
|
| Liver Diseases | 1 | 2019 | 32 | 0.150 |
Why?
|
| Allografts | 1 | 2019 | 203 | 0.150 |
Why?
|
| Pandemics | 1 | 2020 | 227 | 0.150 |
Why?
|
| Age Factors | 1 | 2020 | 716 | 0.150 |
Why?
|
| Male | 5 | 2022 | 13917 | 0.150 |
Why?
|
| Leukemia, Myelomonocytic, Chronic | 1 | 2017 | 2 | 0.140 |
Why?
|
| Child | 1 | 2020 | 1277 | 0.130 |
Why?
|
| Treatment Outcome | 1 | 2020 | 3231 | 0.100 |
Why?
|
| Female | 4 | 2023 | 14273 | 0.090 |
Why?
|
| Chromosome Aberrations | 2 | 2021 | 9 | 0.090 |
Why?
|
| Remission Induction | 2 | 2022 | 80 | 0.080 |
Why?
|
| Survival Rate | 2 | 2018 | 308 | 0.070 |
Why?
|
| Toes | 1 | 2023 | 6 | 0.050 |
Why?
|
| Voriconazole | 1 | 2023 | 12 | 0.050 |
Why?
|
| Cohort Studies | 2 | 2022 | 1781 | 0.050 |
Why?
|
| Antifungal Agents | 1 | 2023 | 43 | 0.050 |
Why?
|
| Unrelated Donors | 1 | 2022 | 5 | 0.050 |
Why?
|
| Siblings | 1 | 2022 | 14 | 0.050 |
Why?
|
| Blast Crisis | 1 | 2020 | 2 | 0.040 |
Why?
|
| Neoplasm Recurrence, Local | 1 | 2022 | 198 | 0.040 |
Why?
|
| Cyclosporine | 1 | 2020 | 13 | 0.040 |
Why?
|
| Stem Cell Transplantation | 1 | 2020 | 38 | 0.040 |
Why?
|
| Betacoronavirus | 1 | 2020 | 65 | 0.040 |
Why?
|
| Alemtuzumab | 1 | 2018 | 5 | 0.040 |
Why?
|
| Multivariate Analysis | 1 | 2018 | 299 | 0.040 |
Why?
|
| Proportional Hazards Models | 1 | 2018 | 332 | 0.040 |
Why?
|
| Bone Marrow Transplantation | 1 | 2017 | 22 | 0.030 |
Why?
|
| Prospective Studies | 1 | 2018 | 1633 | 0.030 |
Why?
|
| Survival Analysis | 1 | 2013 | 246 | 0.030 |
Why?
|